drugset / Trial / NCT07064486

A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia

NCT07064486

Phase 3 Recruiting 477 enrolled BrightGene Bio-Medical Technology Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Indonesia. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin in patients with type 2 diabetes

Timeline

Start
2025-07-04
Primary completion
2026-07-31
Completion
2026-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject BGM0504 Unknown 5 mg Subcutaneous
Subject BGM0504 Unknown 10 mg Subcutaneous
Comparator Semaglutide Peptide 1 mg Subcutaneous